{"filing":{"accession_number":"0000078003-26-000085","cik":"0000078003","ticker":"PFE","company_name":"PFIZER INC","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"pfe-20260618.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000085/pfe-20260618.htm"},"events":[{"id":11691,"run_id":10274,"accession_number":"0000078003-26-000085","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Dave Denton, Chief Financial Officer, is stepping down from his position effective August 15, 2026, to pursue a professional opportunity outside the pharmaceutical industry. While the filing also discloses the interim appointment of Cecile Guegan as Interim CFO, the principal disclosed action centers on Denton's departure—a material executive departure at the C-suite level. The CFO role is critical to investor assessment of financial stewardship and strategy execution.","company_name":"PFIZER INC","ticker":"PFE","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8343,"accession_number":"0000078003-26-000085","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Dave Denton, Chief Financial Officer, is stepping down from his position effective August 15, 2026, to pursue a professional opportunity outside the pharmaceutical industry. While the filing also discloses the interim appointment of Cecile Guegan as Interim CFO, the principal disclosed action centers on Denton's departure—a material executive departure at the C-suite level. The CFO role is critical to investor assessment of financial stewardship and strategy execution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T11:08:06.590791+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8343,"accession_number":"0000078003-26-000085","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Dave Denton, Chief Financial Officer, is stepping down from his position effective August 15, 2026, to pursue a professional opportunity outside the pharmaceutical industry. While the filing also discloses the interim appointment of Cecile Guegan as Interim CFO, the principal disclosed action centers on Denton's departure—a material executive departure at the C-suite level. The CFO role is critical to investor assessment of financial stewardship and strategy execution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T11:08:06.590791+00:00","company_name":"PFIZER INC","ticker":"PFE","filing_date":"2026-06-18"}]}